External broker reports(aggregated public sources), Prabhudas Lilladhar

Prabhudas Lilladhar

External broker reports(aggregated public sources)

Prabhudas Lilladher is one of India's leading research based financial services organisation.

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Jupiter Life Line Hospitals / Equity Bottom-Up

<ul><li>Jupiter Life Line Hospitals (JLHL) Q3 consolidated EBITDA grew by 21% YoY (flat QoQ) to Rs. 750mn; in line with our estimates aided by higher ARPOB and case mix.</li><li>JLHL’s operational efficiency has been strong in competitive markets of MMR.</li><li>The company reported Revenue/EBITDA CAGR of 24%/35% over FY21- 24.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Jupiter Life Line Hospitals (JLHL) Q3 consolidated EBITDA grew by 21% YoY (flat QoQ) to Rs. 750mn; in line with our estimates aided by higher ARPOB and case mix.JLHL’s operational efficiency has been strong in competitive markets of MMR.The company reported Revenue/EBITDA CAGR of 24%/35% over FY21- 24.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Jupiter Life Line Hospitals - Growth Levers Intact with Strategic Expansions

<ul><li>Prabhudas Lilladher's research report onJupiter Life Line Hospitals Jupiter Life Line Hospitals (JLHL) Q4 consolidated EBITDA grew by 21% YoY (1% QoQ) to Rs.</li><li>623mn; in line with our estimates aided by higher ARPOB.</li><li>JLHL’s operational efficiency has been strong in competitive markets of MMR.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Prabhudas Lilladher's research report onJupiter Life Line Hospitals Jupiter Life Line Hospitals (JLHL) Q4 consolidated EBITDA grew by 21% YoY (1% QoQ) to Rs.623mn; in line with our estimates aided by higher ARPOB.JLHL’s operational efficiency has been strong in competitive markets of MMR.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Jupiter Life Line Hospitals - In-Line Quarter; Margins to Improve

India

Jupiter Life Line Hospitals Limited operates as a hospital. The Company offers cardiology, paediatrics, rehabilitation, organ transplant, haematology, surgical gastroenterology, internal medicine, and cancer care services. Jupiter Life Line Hospitals serves patients in India.

Jupiter Life Line Hospitals (0372574D IN)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jupiter Life Line Hospitals (0372574D IN)

Jupiter Life Line Hospitals - Growth Levers Intact with Strategic Expansions

Jupiter Life Line Hospitals (JLHL) Q3 consolidated EBITDA grew by 21% YoY (flat QoQ) to Rs. 750mn; in line with our estimates aided by higher ARPOB...

Prabhudas Lilladhar

Jupiter Life Line Hospitals - In-Line Quarter; Margins to Improve

Prabhudas Lilladher's research report onJupiter Life Line Hospitals Jupiter Life Line Hospitals (JLHL) Q4 consolidated EBITDA grew by 21% YoY (1%...

Prabhudas Lilladhar

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)